Xconomy National

Archives

by in

Entry	Author	Date	Location
Celgene Buys Avila for $350M, Gaining Promising “Covalent” Drugs	Arlene Weintraub	01/26/12	Boston
(Mis)Understanding Drug Discovery: It’s Much Harder Than Rocket Science	Stewart Lyman	09/07/11	Seattle
Sanofi Collaboration Drives Regeneron’s Transformation From R&D House to Commercial Player	Arlene Weintraub	07/13/11	New York
Allozyne’s Backdoor IPO, Sound Pharma Fights iPod Deafness, Mirina Vs. Marina Ends, & More Seattle-Area Life Sciences News	Luke Timmerman	06/23/11	Seattle
Pfizer Adds to Data on Novel RA Drug	Arlene Weintraub	04/28/11	New York
BG Medicine Chief Speaks on Rough IPO Climate, (Finally) Going Public	Ryan McBride	04/21/11	Boston
Pfizer Releases Top Line Data on Novel RA Drug	Arlene Weintraub	04/15/11	New York
Targeted Genetics, Re-invented as AmpliPhi, Bets on Anti-Bacterials, Moves HQ to London	Luke Timmerman	03/09/11	Seattle
Diagnostics Are Warming Up in Era of Fast, Cheap Sequencing, Says MDV’s Rowan Chapman	Luke Timmerman	02/07/11	San Francisco
Acceleron Pharma Cuts 40 Percent of Workforce	Luke Timmerman	11/03/10	Boston
Via Science Forms to Launch “Big Data” Analytics Startups	Ryan McBride	11/02/10	Boston
Montgomery Joins Alder Board	Luke Timmerman	11/01/10	Seattle
Amylin Regroups From FDA Smackdown, CalciMedica Plans Trial of New Anti-Immune Drug, FDA Gives CareFusion Recall Highest Priority, & More San Diego Life Science News	Bruce V. Bigelow	10/21/10	San Diego
CalciMedica Charges Ahead Toward First Human Test of Oral Pill for Psoriasis	Luke Timmerman	10/20/10	San Diego
Rigel Nabs $25M From AstraZeneca	Luke Timmerman	09/29/10	San Francisco
Rigel Arthritis Drug Passes Trial	Luke Timmerman	09/23/10	San Francisco
Cytomx, Backed by Third Rock & Roche, Raises $30M for New Class of Antibodies	Luke Timmerman	09/23/10	San Francisco
Glaxo’s Tempero Pharma Advances on Hot Niche of Immunology	Ryan McBride	07/15/10	Boston
Femta Pharmaceuticals Snags $2.2M for Potent Antibody Drugs	Luke Timmerman	07/13/10	San Diego
Gilead Buys CGI for Up To $120M	Luke Timmerman	06/25/10	San Francisco
Pfizer Dumps Trubion’s Lead Rheumatoid Arthritis Drug, Keeps Next-Gen Product Alive	Luke Timmerman	06/14/10	Seattle
Biotech Drug Discovery in Seattle: A Look Back	Stewart Lyman	06/11/10	Seattle
Alder, Bristol Arthritis Drug Shows “Outstanding” Results in Trial, Lead Researcher Says	Luke Timmerman	05/17/10	Seattle
Alder Seeks to Treat Cancer in a Radical Way, Fighting Inflammation, Not Tumors	Luke Timmerman	05/13/10	Seattle
Lycera Keeps Its Investors Happy, Snags $11M to Pursue New Autoimmune Drugs	Luke Timmerman	04/28/10	Detroit
Innovation Northwest Wrapup: Alder, Tekmira, Acucela, & Other Emerging Little Biotechs	Luke Timmerman	03/19/10	Seattle
Sage Bionetworks Strikes Deal With Pfizer to Find Cancer Drug Targets	Luke Timmerman	01/11/10	Seattle
Alder Rival Wins FDA Approval	Luke Timmerman	01/09/10	Seattle
Lycera, a Midwestern Biotech Star, Moves Head Office to Boston, Hires Biogen Vet as CEO	Luke Timmerman	01/07/10	Boston
Alder Rises From Ashes of Layoffs to Become Seattle Biotech Force	Luke Timmerman	01/04/10	Seattle
Page 1 of 3	next page »